Perrigo (PRGO) Misses Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Perrigo Co. (PRGO) PT Lowered to $48 at RBC Capital
February 28, 2019 6:48 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Perrigo Co. (NYSE: PRGO) to $48.00 (from $50.00) while maintaining a Sector Perform rating following results.
Stanicky notes consumer margins are under pressure and they stay cautious into the May update.
... MorePerrigo (PRGO) Receives Leave To Judicially Review Irish Revenue Tax Assessment
February 25, 2019 8:39 AM ESTllPerrigo Company plc (NYSE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan Pharma"), has been granted leave by the Irish High Court to judicially review the November 29, 2018 issuance of a Notice of Amended Assessment by the Irish Office of the Revenue Commissioners for the calendar year ended December 31, 2013.
As... More
